Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH35 in KRAS G12C-mutated advanced solid tumors
NCT05010694Phase 1Active, not recruiting
- Sponsor
- Genhouse Bio
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GH35 in solid tumor (advanced stage), sponsored by Genhouse Bio. Primary endpoint: Dose-limiting toxicities at 24 Days. Started Sep 2021; status: active, not recruiting.
02
Drugs
GH35
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05010694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05010694.